Pilot Study Using Myeloblative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma
R
Robert Fallon, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
30 years or below
All
Phase
N/A
1 Location
Brief description of study
This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma.
Detailed description of study
In this study, researchers want to find out if a combination of busulfan and melphalan (BuMel) can be given as Consolidation therapy prior to ASCT for subjects with newly diagnosed high-risk NBL.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Brain Cancer
-
Age: 30 years or below
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 1304011168 (ANBL12P1)
